Anzeige
Erschienen in:
21.01.2020 | Correction
Correction to: Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura
Erschienen in: Intensive Care Medicine | Ausgabe 3/2020
Einloggen, um Zugang zu erhaltenExcerpt
The original version of this article unfortunately contained a mistake. The penultimate row of Table 4 shows INR > 1.5 which is incorrect. The correct figure is INR < 1.5. The authors apologize for the mistake. The correct table is given below.
Table 4
Clinical criteria and scoring systems for diagnosing ADAMTS13 deficiency
|
Clinical predictors of ADAMTS13 deficiency. Coppo et al. 2010a
|
|
|---|---|
|
Creatinine < 200 μmoL/L
Platelet count < 30 × 109/L
Positive antinuclear antibodies
|
Three criteria predict severe ADAMTS13 deficiency with 98% (94–100%) specificity, 47% (41–53%) sensitivity, 99% (96–100%) positive predictive value and 39% (36–42%) negative predictive value
|
|
Point-based ADAMTS13 deficiency prediction score. Bentley et al. 2010b,c
|
||
|---|---|---|
|
Points
|
Probability of severe ADAMTS13 deficiency
|
|
|
Creatinine > 2.0 mg/dL
|
− 11.5
|
|
|
Platelets > 35 × 109/L
|
− 30
|
> 30 points, 100%
|
|
D-dimer > 4.0 µg/mL
|
− 10
|
20–30 points, 40%
|
|
Reticulocytes > 3%
|
+ 21
|
< 20 points, 0% probability
|
|
Indirect bilirubin > 1.5 µg/mL
|
+ 20.5
|
|
|
PLASMIC score. Bendapudi et al. 2016d
|
||
|---|---|---|
|
Points
|
||
|
Platelet count < 30 × 109/L
|
1
|
Risk of severe ADAMTS13 deficiency
|
|
Combined hemolysis variablese
|
1
|
≤ 4, low
|
|
No active malignancy
|
1
|
5, intermediate
|
|
No history of transplantation
|
1
|
6 or 7, risk >80%
|
|
MCV< 9 × 10−14 L
|
1
|
Median score in patients with confirmed TTP was 7 (IQR, 6–7)
|
|
INR < 1.5
|
1
|
|
|
Creatinine < 2.0 mg/dL
|
1
|
|